ScienceDaily (Jan. 30, 2012) ? Hispanic children are more likely than those from other racial and ethnic backgrounds to be diagnosed with acute lymphoblastic leukemia (ALL) and are more likely to die of their disease. Work led by St. Jude Children's Research Hospital scientists has pinpointed genetic factors behind the grim statistics.
Researchers studying a gene called ARID5B linked eight common variants of the gene to an increased risk of not only developing pediatric ALL but of having the cancer return after treatment. Two more ARID5B variants were tied to higher odds of developing the disease. Investigators found that Hispanic children were up to twice as likely as their white counterparts to inherit a high risk-version of ARID5B.
"For years we have known about ethnic and racial disparities in ALL risk and outcome, but the biology behind it has been elusive. Therefore, it is truly exciting to be able to not only pin down the biological basis but to find that the same gene might be responsible for both differences. Children who inherit high-risk versions of ARID5B are more likely to develop ALL in the first place and then more likely to fail therapy," said Jun Yang, Ph.D., an assistant member of the St. Jude Department of Pharmaceutical Sciences and the paper's corresponding author.
The work was done in collaboration with the Children's Oncology Group (COG), a U.S. based research cooperative study group focused on childhood cancer research and clinical trials. The study appears in the January 30 online edition of the Journal of Clinical Oncology.
Multiple factors contribute to cancer development, and inheriting a high-risk version of ARID5B is not enough to cause the disease, Yang said. These findings set the stage for exciting research in understanding how genetic, environmental and other factors combine in ALL, especially in the context of racial and ethnic disparity, he said.
"These and other genomic studies suggest we are poised to finally make significant progress in eliminating racial disparities in this catastrophic disease," Yang said. Additional work is needed to translate these findings into new clinical tools, he added.
Each year ALL is found in about 3,000 U.S. children, making it the most common childhood cancer. The incidence varies by self-declared race and ethnicity with rates for Hispanic individuals 50 percent higher than for non-Hispanic white individuals. For this study, researchers used genetic variations rather than individual self-report to define ancestry. White children were defined as having greater than 95 percent European ancestry and Hispanics children as having greater than 10 percent Native American ancestry.
Although the work of St. Jude researchers and others is helping to close the survival gap, Hispanic children are still less likely than children from other racial or ethnic backgrounds to be alive five years after diagnosis.
This study builds on the earlier St. Jude research that linked different versions of the ARID5B gene to ALL risk.
St. Jude and COG investigators partnered to see if variations in the ARID5B gene help to explain differences in either the incidence or the outcome of ALL in white and Hispanic patients. ARID5B belongs to a family of genes called transcription factors. They play a role in the normal development of white blood cells, which are targeted in ALL. Evidence suggests the gene also influences how methotrexate, a key anti-leukemia drug, is metabolized.
To find ARID5B variants related to ALL, the study compared the gene in 330 Hispanic children with ALL and 541 Hispanic individuals without ALL. Researchers also checked ARID5B in 978 white ALL patients and 1,046 white individuals without the cancer.
Although the high-risk versions of ARID5B were found in both white and Hispanic patients, those variants were 1.5 to two times more common in Hispanic children than in white children.
Individuals inherit two copies of every gene, one from each parent. Children with one high-risk version of ARID5B were up to 80 percent more likely to develop ALL than others. Inheriting two copies of a high-risk version of the gene translated into a 3.6-fold increased ALL risk.
Researchers also found evidence linking ARID5B variants to relapse risk in 1,605 pediatric ALL patients enrolled in COG studies. Yang and his colleagues previously linked that level of Native American ancestry to a higher relapse risk in Hispanic ALL patients. Patients in this study who inherited a high-risk version of ARID5B were 50 percent more likely to relapse than other patients. They were also more likely to die of their cancer.
The study's first author is Heng Xu of St. Jude. Other authors are Cheng Cheng, Deqing Pei, Yiping Fan, Wenjian Yang, Geoff Neale, William E. Evans, Ching-Hon Pui, and Mary Relling, all of St. Jude; Meenakshi Devidas, University of Florida, Gainesville; Paul Scheet, University of Texas MD Anderson Cancer Center; Esteban Gonzalez Burchard, Dara Torgerson, Celeste Eng and Mignon Loh, all of University of California, San Francisco; Michael Dean, National Cancer Institute; Federico Antillon, Unidad Nacional de Oncologia Pediatrica, Guatemala; Naomi Winick, University of Texas Southwestern Medical Center; Paul Martin, Duke University; Cheryl Willman, University of New Mexico; Bruce Camitta, Medical College of Wisconsin; Gregory Reaman, George Washington University, Children's National Medical Center; William Carroll, New York University; and Stephen Hunger, University of Colorado School of Medicine and Children's Hospital Colorado.
Yang was supported by the American Society of Hematology Scholar Award and the Alex Lemonade Stand Foundation for Childhood Cancer Young Investigator Award. The work was supported in part by the National Institutes of Health, the Jeffrey Pride Foundation, CureSearch and ALSAC.
Recommend this story on Facebook, Twitter,
and Google +1:
Other bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by St. Jude Children's Research Hospital, via Newswise.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Heng Xu, Cheng Cheng, Meenakshi Devidas, Deqing Pei, Yiping Fan, Wenjian Yang, Geoff Neale, Paul Scheet, Esteban G. Burchard, Dara G. Torgerson, Celeste Eng, Michael Dean, Frederico Antillon, Naomi J. Winick, Paul L. Martin, Cheryl L. Willman, Bruce M. Camitta, Gregory H. Reaman, William L. Carroll, Mignon Loh, William E. Evans, Ching-Hon Pui, Stephen P. Hunger, Mary V. Relling, and Jun J. Yang. RID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012; DOI: 10.1200/JCO.2011.38.0345
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
Source: http://www.sciencedaily.com/releases/2012/01/120130172619.htm
99% associated press breast cancer awareness breast cancer awareness guinea worm the others the others
Anzati are similar to humans, the only differences being two prehensile probosci and a somewhat enlarged nose. People of their species are rare, but they have an impressive lifespan that can last for over a millennium. The proboscises lie coiled and hidden in pockets within the cheeks and can be extended to drain a victim's 'luck' or 'soup' by piercing the brain through the nose. The Anzati are capable of mild telepathic control to render their victims paralyzed, and are assassins of legendary skill. The Jedi hunting mercenary Aurra Sing was trained by these assassins, as was the Jedi Master Tholme. Their planet of origin has never been verified, as all sent to investigate the planet suspected to be Anzat are never seen again. Two more famous Anzati were Dannik Jerriko, an assassin of great renown who hunted Han Solo, as written in "Tales From Mos Eisley Cantina."[3] and the dark Jedi Nikkos Tyris.
Of course, you shouldn?t keep your investment small over time. While it is important to get started with investing, you should also increase the amount you invest as your income increases. As you earn more money, increase what you are contributing. Don?t think that you are going to earn enough money to retire on if you stick with your original plan of investing $50 a month. That?s just not going to cut it. As your circumstances improve, you must take your investing up a notch. Just make sure to consider your asset allocation and rebalance occasionally to limit your risk, and improve your portfolio performance.